

Causes of cholestasis in the newborn, which presents as direct or conjugated hyperbilirubinemia. (See "Causes of cholestasis in the newborn, which presents as direct or conjugated hyperbilirubinemia".)

## DEFINITIONS

Although there is no consensus amongst experts in the field in defining the clinical significance of bilirubin levels for term and late preterm infants, the authors use the following definitions in this document:

- Benign neonatal hyperbilirubinemia is a transient and normal increase in bilirubin levels, often referred to as "physiologic" jaundice.
- Significant hyperbilirubinemia in infants  $\geq 35$  weeks gestational age (GA) is defined by a nomogram ([figure 1](#)) [1].
- Severe neonatal hyperbilirubinemia is defined as a TB  $> 25$  mg/dL (428 micromol/L).
- Extreme **neonatal hyperbilirubinemia** is defined as a TB  $> 30$  mg/dL (513 micromol/L).
- **BIND** is due to brain damage from free bilirubin that crosses the blood-brain barrier and causes molecular and cytological injuries of brain cells. (See "[Unconjugated hyperbilirubinemia in term and late preterm infants: Epidemiology and clinical manifestations](#)", section on '[Clinical manifestations](#)').
  - Acute bilirubin encephalopathy (ABE) is used to describe the acute manifestations of unconjugated hyperbilirubinemia in term and late preterm infants: [Epidemiology and clinical manifestations](#), section on '[Acute bilirubin encephalopathy](#)'.)
  - Chronic bilirubin encephalopathy (CBE, previously referred to as kernicterus) is used to describe the chronic manifestations of unconjugated hyperbilirubinemia in term and late preterm infants: [Epidemiology and clinical manifestations](#), section on '[Chronic bilirubin encephalopathy \(kernicterus\)](#)'.)

## BILIRUBIN METABOLISM

Knowledge of the basic steps in bilirubin metabolism is essential to the understanding of bilirubin metabolism. Bilirubin metabolism is briefly reviewed here and is discussed in detail separately ([figure 2](#)).

conjugated bilirubin. The unconjugated bilirubin is reabsorbed through the intestine as the enterohepatic circulation of bilirubin.

## BENIGN NEONATAL HYPERBILIRUBINEMIA

**Mechanism** — Benign neonatal hyperbilirubinemia (also previously referred to as "pbilirubin) bilirubinemia that occurs in nearly all newborns [2]. It is a normal transitional state between fetal and adult metabolism. It is due to decreased activity of hepatic enzymes, the immaturity of the newborn's liver to efficiently metabolize bilirubin, and increased bilirubin production.

Normal adult total serum or plasma bilirubin (TB) levels are <1 mg/dL, while term newborns have approximately 8 to 9 mg/dL because:

- Newborns have more red blood cells (hematocrit between 50 to 60 percent), and therefore a higher bilirubin load than adults (approximately 10 times greater than those in adults at 85 days) than those in adults. After birth there is an increased turnover of fetal red blood cells, which increases bilirubin production.
- Bilirubin clearance (conjugation and excretion) is decreased in newborns, mainly due to low activity of the enzyme uridine diphosphoglucuronyltransferase (UGT1A1). UGT activity in term infants is only about 20% of the adult liver and does not reach adult levels until 14 weeks of age [3,4].
- There is an increase in the enterohepatic circulation of bilirubin as the amount of conjugated bilirubin is reduced due to decreased hepatic uptake and excretion. This further increasing the bilirubin load in the infant. (See '[Bilirubin clearance and metabolism](#)' for more information).

**Peak TB levels and time to resolution** — Peak total serum or plasma bilirubin (TB) and time to resolution vary based on ethnicity and gestational age (GA), likely because of differences in hepatic uptake, clearance, and excretion.

- Peak TB – Both the height and the timing of peak TB typically vary based on ethnicity and gestational age.
  - In Caucasian and African American term infants, the mean TB levels peak at 4 to 5 mg/dL (71 to 85 micromol/L). The 95<sup>th</sup> percentile ranges from 13 to 18 mg/dL (222 to 308 micromol/L).
  - In some East-Asian infants, mean TB levels can peak to 10 to 14 mg/dL (171 to 235 micromol/L) by 120 hours of age.
- Time to resolution – Visible jaundice resolves within the first one to two weeks after birth in most term infants. It usually disappears by 2 weeks in formula-fed Caucasian and African American infants, and by the 10<sup>th</sup> day in Asian infants. In exclusively breastfed newborns, although approximately one in five infants will have hyperbilirubinemia beyond two weeks of age has been labelled as prolonged hyperbilirubinemia.

production due to hemolytic disease processes, such as [8,11,12,14-18]:

- Isoimmune-mediated hemolysis (eg, ABO or Rh[D] incompatibility) [19]. (See "[Management during pregnancy](#)" and "[Postnatal diagnosis and management of hemolytic disease of the newborn](#)".)
- Inherited red blood cell membrane defects (eg, hereditary spherocytosis and elliptocytosis and related disorders".)
- Erythrocyte enzymatic defects (eg, glucose-6-phosphate dehydrogenase [G6PD] deficiency and congenital erythropoietic porphyria). (See "[Diagnosis and management of glucose-6-phosphate dehydrogenase deficiency](#)" and "[Congenital erythropoietic porphyria](#)".)
- Sepsis – The mechanism is not known; however, one theory suggests that increased destruction of red blood cells [8].
- Other causes of increased bilirubin production due to increased red blood cell breakdown within a closed space, such as in cephalohematomas. (See "[Neonatal polycythemia](#)".)
- Macrosomic infants of diabetic mothers (IDM) have increased bilirubin production. (See "[Infants of women with diabetes](#)".)

**Decreased clearance** — Inherited defects in the gene that encodes UGT1A1, which can decrease bilirubin conjugation. This reduces hepatic bilirubin clearance and increases bilirubin levels. These disorders include Crigler-Najjar syndrome types I and II and Gilbert syndrome. These will be detailed separately. (See "[Crigler-Najjar syndrome](#)" and "[Gilbert syndrome and unconjugated hyperbilirubinemia](#)".)

**Crigler-Najjar syndrome** — There are two variants of Crigler-Najjar syndrome. (See "[Crigler-Najjar syndrome](#)".)

- Crigler-Najjar syndrome type I (CN-I) – This is the most severe form of inherited UGT deficiency. Severe hyperbilirubinemia develops in the first two to three days after birth. Lifelong bilirubin-induced neurologic dysfunction (BIND) unless liver transplantation is performed.
- Crigler-Najjar syndrome type II (CN-II) – CN-II is less severe than is CN-I. UGT activity is normal, but bilirubin levels are elevated. Patients with CN-II may never develop severe jaundice, the hyperbilirubinemia often responds to [phenobarbital](#), and inheritance is in a recessive manner, although autosomal dominant transmission occurs in some cases.

**Gilbert syndrome** — Gilbert syndrome is the most common inherited disorder of bilirubin metabolism. It is caused by a defect in the enzyme UGT1A1, which is encoded by a gene. In white and African American patients, it results from a mutation in the promoter of the gene, leading to reduced production of UGT, resulting in unconjugated hyperbilirubinemia. In the East Asian population, it results from a mutation in the gene itself.

impaired intestinal motility caused by functional or anatomic obstruction and possibly latter has not been confirmed.

**Breast milk jaundice** — Breast milk jaundice is defined as the persistence of benign weeks of age. It typically presents after the first three to five days of life, peaks within levels over 3 to 12 weeks [9,35]. Breast milk jaundice needs to be distinguished from suboptimal fluid and caloric intake during the first seven days of life. (See '[Lactation failure](#)'

In infants with jaundice who exclusively receive human milk, TB levels >5 mg/dL (86 μmol/L) Although the hyperbilirubinemia is generally mild and typically does not require intervention, the unconjugated form and does not increase. If TB levels begin to increase or there is concern for other causes of hyperbilirubinemia should be performed. In the case of elevated conjugated bilirubin, further investigation should be considered. If after evaluation human milk intake is the only remaining viable factor, however, it is reasonable to continue feeding in the zone with the expectation of resolution by 12 weeks of age [36]. (See '[Unconjugated hyperbilirubinemia in breastfed infants](#)' and '[Causes of cholestasis in neonates and young infants](#)' and '[Approach to jaundiced newborns](#)'

The underlying mechanism of "breast milk jaundice" is not conclusively known. Human milk contains beta-glucuronidase, an enzyme which catalyzes the hydrolysis of beta-D-glucuronic acid [37]. In contrast, there is negligible beta-glucuronidase activity in human milk. Formula-fed infants have lower levels of bilirubin than those who receive human milk [38]. Beta-glucuronidase degradation of bilirubin to biliverdin and subsequent conversion to bilirubin glucuronic acid due to increased degradation is thought to promote an increase in intestinal absorption of bilirubin. Beta-glucuronidase inhibitors, such as enzymatically-hydrolyzed casein or L-aspartic acid, have been used prophylactically in breastfed newborns [40]. However, the prolonged unconjugated hyperbilirubinemia associated with these agents is likely benign, and there appears to be no benefit for the use of these agents [41]. As a result, discontinuation of human milk is not recommended for breast milk jaundice.

Another potential underlying mechanism is polymorphic mutation of the *UGT1A1* gene. In breastfed infants with breast milk jaundice, half of infants were homozygous for the *UGT1A1\*6* genotype [42]. These infants have a reduced ability to conjugate bilirubin due to the presence of two functional polymorphisms. The *UGT1A1\*6* genotype was not detected in control infants. However, the clinical significance of this finding is unknown, and further studies are needed to determine whether there is a causal relationship between genetic variation of the *UGT1A1* gene and breast milk jaundice. Testing for the *UGT1A1* genotype should not be used in the evaluation of breast milk-related jaundice.

**Ileus or intestinal obstruction** — Ileus or anatomic causes of intestinal obstruction can result in jaundice. TB levels are frequently higher with small bowel than with large bowel obstruction. For example, 90 percent of infants with pyloric stenosis when vomiting begins. (See '[Infantile hypertrophic pyloric stenosis](#)' and '[Intestinal obstruction](#)'

**Lactation failure jaundice** — Lactation (breastfeeding) failure jaundice typically occurs in breastfed infants with inadequate intake of fluids and calories resulting in hypovolemia and significant weight loss.

UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics". The Basics articles are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions that patients most often have about their condition. These articles are best for patients who want a general overview and who prefer shorter, easier-to-read pieces of information. Beyond the Basics articles are longer, more sophisticated, and more detailed. These articles are intended for patients who want in-depth information and are comfortable with some medical jargon.

Here are the patient education articles that are relevant to this topic. We encourage you to read them. You can also locate patient education articles on a variety of subjects by searching on "patient education" in the search bar.

- Beyond the Basics topics (see ["Patient education: Jaundice in newborn infants \(Beyond the Basics\)"](#))

---

## SUMMARY


- Total serum or plasma bilirubin (TB) levels >1 mg/dL (17 micromol/L) occur in almost all term newborns. Infants with severe hyperbilirubinemia (TB >25 mg/dL [428 micromol/L]) are at risk for developing acute bilirubin encephalopathy (ABE) if untreated. Untreated ABE can lead to permanent neurologic sequelae of chronic bilirubin encephalopathy (CBE, previously referred to as kernicterus).
- Benign ("nonpathologic") neonatal hyperbilirubinemia, previously referred to as "physiologic jaundice", is caused by the turnover of fetal red blood cells, immaturity of the newborn's liver that cannot clear bilirubin effectively, resulting in decreased bilirubin clearance and increased enterohepatic circulation. Mean TB levels normally peak at 7 to 9 mg/dL (121 to 154 micromol/L) in non-Hispanic American infants and are higher in Asian infants, 10 to 14 mg/dL (171 to 239 micromol/L).
- Hyperbilirubinemia is due to increased bilirubin load either due to an increase in bilirubin production (See ['Causes of significant unconjugated hyperbilirubinemia in term newborns'](#)) or decreased bilirubin clearance (See ['Causes of significant conjugated hyperbilirubinemia in term newborns'](#)).
- For infants with severe and extreme hyperbilirubinemia, identification of the cause is important so that therapeutic interventions are needed and their timing. (See ['Causes of significant hyperbilirubinemia in term newborns'](#).)
- Causes of significant unconjugated neonatal hyperbilirubinemia can be classified into three categories:
  - Increased production of bilirubin – Hemolytic disease, polycythemia, and sequelae of hypoxic-ischemic brain injury. Bilirubin is produced because of increased red cell breakdown. (See ['Increased production of bilirubin'](#).)
  - Increased enterohepatic circulation of bilirubin – Breast milk jaundice and impaired hepatic metabolism. Bilirubin is reabsorbed from the gut and returned to the liver. Bile duct obstruction increase enterohepatic circulation of bilirubin. (See ['Increased enterohepatic circulation of bilirubin'](#).)
  - Impaired hepatic metabolism of bilirubin – Gilbert syndrome, Dubin-Johnson syndrome, and Crigler-Najjar syndrome. Bilirubin is not cleared from the blood because the liver does not produce enough of the enzyme that converts bilirubin to a water-soluble form. (See ['Impaired hepatic metabolism of bilirubin'](#).)

8. Kaplan M, Wong RJ, Sibley E, Stevenson DK. Neonatal jaundice and liver disease. In: *The textbook of the newborn infant*, 9th ed, Martin RJ, Fanaroff AA, Walsh MC (Eds), Elsevier Mosby, St. Louis 2007; 1:111-11.
9. Maisels MJ, Clune S, Coleman K, et al. The natural history of jaundice in predominantly healthy term infants. *J Pediatr* 1998; 132:101-6.
10. Fawaz R, Baumann U, Ekong U, et al. Guideline for the Evaluation of Cholestatic Jaundice in Children. *Journal of the American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and Journal of Pediatric Hepatology, and Nutrition*. *J Pediatr Gastroenterol Nutr* 2017; 64:154.
11. Beutler E, Gelbart T, Demina A. Racial variability in the UDP-glucuronosyltransferase regulation of bilirubin metabolism? *Proc Natl Acad Sci U S A* 1998; 95:8170.
12. Akaba K, Kimura T, Sasaki A, et al. Neonatal hyperbilirubinemia and mutation of the *UGT1A1* gene: a common missense mutation among Japanese, Koreans and Chinese. *Biochem Biophys Res Commun* 2000; 270:100-4.
13. Long J, Zhang S, Fang X, et al. Neonatal hyperbilirubinemia and Gly71Arg mutation of the *UGT1A1* gene: a systematic review of existing evidence. *Acta Paediatr* 2011; 100:966.
14. MacDonald MG. Hidden risks: early discharge and bilirubin toxicity due to glucuronyl transferase deficiency. *J Pediatr* 1996; 129:734.
15. Slusher TM, Vreman HJ, McLaren DW, et al. Glucose-6-phosphate dehydrogenase deficiency associated with bilirubin-related morbidity and death in Nigerian infants. *J Pediatr* 2000; 137:100-4.
16. Johnson JD, Angelus P, Aldrich M, Skipper BJ. Exaggerated jaundice in Navajo newborns. *J Pediatr* 1999; 135:889.
17. Fischer AF, Nakamura H, Uetani Y, et al. Comparison of bilirubin production in Japanese and American newborns. *J Pediatr* 1988; 112:727.
18. Watchko JE, Lin Z, Clark RH, et al. Complex multifactorial nature of significant hyperbilirubinemia in term newborns. *J Pediatr* 2000; 137:105-11.
19. Kaplan M, Hammerman C, Vreman HJ, et al. Direct antiglobulin titer strength and bilirubin production in term newborns. *J Pediatr* 2000; 137:105-11.
20. Riskin A, Gery N, Kugelman A, et al. Glucose-6-phosphate dehydrogenase deficiency and hyperbilirubinemia. *J Pediatr* 2012; 161:191.
21. Skierka JM, Kotzer KE, Lagerstedt SA, et al. UGT1A1 genetic analysis as a diagnostic tool for hyperbilirubinemia. *J Pediatr* 2013; 162:1146.

33. [Huang MJ, Kua KE, Teng HC, et al. Risk factors for severe hyperbilirubinemia in newborns of diabetic mothers. J Perinatol 2008; 28: 791-795.](#)
34. [Stevenson DK, Ostrander CR, Hopper AO, et al. Pulmonary excretion of carbon monoxide in breastfed infants: a possible delayed clearance of bilirubin in infants of diabetic mothers. J Pediatr 1991; 120: 101-105.](#)
35. [Grunebaum E, Amir J, Merlob P, et al. Breast milk jaundice: natural history, familiality, and risk factors. Eur J Pediatr 1991; 150: 267-270.](#)
36. [Preer GL, Philipp BL. Understanding and managing breast milk jaundice. Arch Dis Child 1991; 67: 101-104.](#)
37. [Gourley GR, Arend RA. beta-Glucuronidase and hyperbilirubinaemia in breast-fed infants. Arch Dis Child 1991; 67: 105-108.](#)
38. [Gourley GR, Kreamer B, Arend R. The effect of diet on feces and jaundice during lactation. Arch Dis Child 1991; 67: 109-112.](#)
39. [Gourley GR, Kreamer B, Cohnen M, Kosorok MR. Neonatal jaundice and diet. Arch Dis Child 1991; 67: 113-116.](#)
40. [Gourley GR, Li Z, Kreamer BL, Kosorok MR. A controlled, randomized, double-blind trial of breast milk versus cow's milk for jaundiced newborns. Pediatrics 2005; 116: 385-389.](#)
41. [Bhutani VK. Abuse of casein hydrolysate formulas for treating infants with severe hyperbilirubinemia. Arch Dis Child 1991; 67: 231-234.](#)
42. [Maruo Y, Morioka Y, Fujito H, et al. Bilirubin uridine diphosphate-glucuronosyltransferase activity in breast milk. J Pediatr 2014; 165: 36-40.](#)

Topic 5020 Version 35.0





Schematic diagram demonstrating the production, metabolism, and excretion of bilirubin.

\*Physiologic mechanisms that reduce the movement of free bilirubin across the blood-brain barrier include binding to plasma albumin and rapid uptake, conjugation, and clearance by the liver. These protective mechanisms are less efficient in neonates (especially preterm infants) and individuals with inherited disorders of bilirubin conjugation. As a result, these patients are at risk for bilirubin-induced neurotoxicity.

Adapted from: Hansen TWR, Bratlid D. Physiology of neonatal unconjugated hyperbilirubinemia. In: Care of the Jaundiced Neonate, Stevenson DK, Maisels MJ, Watchko JF (Eds), McGraw-Hill Companies, New York 2012.

Graphic 121543 Version 4.0

glucuronides (BG) prior to excretion. Bilirubin also enters hepatocytes by passive diffusion. Glucuronidation of bilirubin is mediated by a family of enzymes, termed uridine diphosphoglucuronosyltransferase (UGT), the most important of which is bilirubin-UGT-1 (UGT1A1). Conjugated bilirubin is secreted actively across the bile canalicular membrane of the hepatocyte against a concentration gradient that may reach 1:1000. The canalicular multi-drug resistance protein 2 (MRP2) appears to be the most important for the canalicular secretion of bilirubin. A portion of the conjugated bilirubin is transported into the sinusoidal blood via the ATP hydrolysis-couple pump, ABCC3, to undergo reuptake via OATP1B1 and OATP1B3 by hepatocytes downstream to the sinusoidal blood flow.

---

UDP: uridine diphosphate; UDPGA: uridine 5'-diphosphoglucuronic acid; ABCC3: ATP-binding cassette subfamily C number 3; OATP1B1: organic anion-transporting polypeptide 1B1; OATP1B3: organic anion-transporting polypeptide 1B3.

Graphic 52393 Version 4.0



















